Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

(RTTNews) - The European Commission has approved Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is indicated ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...

-- UPLIZNA is under review by the European Medicines Agency (EMA) and was approved by the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare as a targeted ...

Please provide your email address to receive an email when new articles are posted on . In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its ...

A systematic review identified 15 studies, enabling a meta-analysis of 443 NMOSD patients with 639 pregnancies. Rates of pregnancy-related NMOSD relapses were highest during the first 3 months ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...